Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celsion Corporation    CLSN

CELSION CORPORATION

(CLSN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/15/2020 10/16/2020 10/19/2020 10/20/2020 10/21/2020 Date
0.6325(c) 0.6242(c) 0.5747(c) 0.5682(c) 0.589 Last
951 924 1 198 312 1 209 458 588 051 546 798 Volume
-5.61% -1.31% -7.93% -1.13% +3.66% Change
More quotes
Financials (USD)
Sales 2020 0,51 M - -
Net income 2020 -19,8 M - -
Net Debt 2020 - - -
P/E ratio 2020 -0,85x
Yield 2020 -
Sales 2021 0,25 M - -
Net income 2021 -17,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,25x
Yield 2021 -
Capitalization 20,5 M 20,5 M -
Capi. / Sales 2020 40,7x
Capi. / Sales 2021 82,2x
Nbr of Employees 29
Free-Float 98,6%
More Financials
Company
Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid... 
More about the company
Notations Surperformance© of Celsion Corporation
Trading Rating : - Investor Rating :
More Ratings
All news about CELSION CORPORATION
10/16CELSION CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Rul..
AQ
10/12CELSION CORPORATION : Issues Letter to Stockholders
AQ
10/12Celsion Corporation Issues Letter to Stockholders
GL
09/08CELSION CORP : Entry into a Material Definitive Agreement, Other Events, Financi..
AQ
09/08CELSION : Announces Common Stock Purchase Agreement with Lincoln Park Capital an..
AQ
09/08Celsion Announces Common Stock Purchase Agreement with Lincoln Park Capital a..
GL
09/04CELSION CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/02CELSION CORP : Entry into a Material Definitive Agreement, Termination of a Mate..
AQ
09/02Celsion Corporation Restructures its Strategic Loan Facility
GL
08/14CELSION : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
08/14CELSION CORP : Results of Operations and Financial Condition, Financial Statemen..
AQ
08/14Celsion Corporation Reports Second Quarter 2020 Financial Results and Provide..
GL
08/07Celsion Corporation to Hold Second Quarter 2020 Financial Results and Busines..
GL
08/04Celsion Corporation to Continue Following Patients in Phase III OPTIMA Study ..
GL
08/03CELSION CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
More news
News in other languages on CELSION CORPORATION

- No features available -

More news
Chart CELSION CORPORATION
Duration : Period :
Celsion Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELSION CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 4,00 $
Last Close Price 0,57 $
Spread / Highest target 604%
Spread / Average Target 604%
Spread / Lowest Target 604%
EPS Revisions
Managers
NameTitle
Michael H. Tardugno Chairman, President & Chief Executive Officer
Jeffrey Wayne Church CFO, Secretary & SVP-Investor Relations
Nicholas Borys Chief Medical Officer & Senior Vice President
Khursheed Anwer Chief Scientific Officer & Executive VP
Pok Yu Chow Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELSION CORPORATION-66.77%21
GILEAD SCIENCES, INC.-6.82%75 938
REGENERON PHARMACEUTICALS53.57%61 364
VERTEX PHARMACEUTICALS-2.01%57 436
WUXI APPTEC CO., LTD.63.88%38 230
BEIGENE, LTD.80.92%27 326